Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Alcon AG vs Citius Pharmaceuticals Inc — how do they compare? Alcon AG trades at $72.55 (market cap $36.44B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Alcon AG is far larger — about 1821.1× Citius Pharmaceuticals Inc's market cap, and Alcon AG pays a 0.48% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

ALCCTXR
Market Cap
$36.44B$20.01M
Sector
HealthHealth
52-Week High
$90.12$1.82
52-Week Low
$62.02$0.48
Enterprise Value
$40.28B$16.23M
Dividend Yield
0.48%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR